Letter | Published:

Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators

Nature volume 546, pages 312315 (08 June 2017) | Download Citation


The glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) are members of the secretin-like class B family of G-protein-coupled receptors (GPCRs) and have opposing physiological roles in insulin release and glucose homeostasis1. The treatment of type 2 diabetes requires positive modulation of GLP-1R to inhibit glucagon secretion and stimulate insulin secretion in a glucose-dependent manner2. Here we report crystal structures of the human GLP-1R transmembrane domain in complex with two different negative allosteric modulators, PF-06372222 and NNC0640, at 2.7 and 3.0 Å resolution, respectively. The structures reveal a common binding pocket for negative allosteric modulators, present in both GLP-1R and GCGR3 and located outside helices V–VII near the intracellular half of the receptor. The receptor is in an inactive conformation with compounds that restrict movement of the intracellular tip of helix VI, a movement that is generally associated with activation mechanisms in class A GPCRs4,5,6. Molecular modelling and mutagenesis studies indicate that agonist positive allosteric modulators target the same general region, but in a distinct sub-pocket at the interface between helices V and VI, which may facilitate the formation of an intracellular binding site that enhances G-protein coupling.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol. Rev. 68, 954–1013 (2016)

  2. 2.

    , & Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol. Ther. 135, 247–278 (2012)

  3. 3.

    et al. Extra-helical binding site of a glucagon receptor antagonist. Nature 533, 274–277 (2016)

  4. 4.

    et al. Crystal structure of the β2 adrenergic receptor–Gs protein complex. Nature 477, 549–555 (2011)

  5. 5.

    , , , & Structure of the adenosine A2A receptor bound to an engineered G protein. Nature 536, 104–107 (2016)

  6. 6.

    et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 455, 497–502 (2008)

  7. 7.

    et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl Acad. Sci. USA 104, 937–942 (2007)

  8. 8.

    et al. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 59, 3099–3107 (2010)

  9. 9.

    et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc. Natl Acad. Sci. USA 104, 943–948 (2007)

  10. 10.

    et al. Structural determinants of binding the seven-transmembrane domain of the glucagon-like peptide-1 receptor (GLP-1R). J. Biol. Chem. 291, 12991–13004 (2016)

  11. 11.

    et al. The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism. Cell 165, 1632–1643 (2016)

  12. 12.

    et al. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J. Biol. Chem. 285, 723–730 (2010)

  13. 13.

    , , , & A hydrophobic site on the GLP-1 receptor extracellular domain orients the peptide ligand for signal transduction. Mol. Metab. 2, 86–91 (2013)

  14. 14.

    et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499, 438–443 (2013)

  15. 15.

    et al. Structure of the human glucagon class B G-protein-coupled receptor. Nature 499, 444–449 (2013)

  16. 16.

    , , , & Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc. Natl Acad. Sci. USA 110, 5211–5216 (2013)

  17. 17.

    , , , & Functional coupling of Cys-226 and Cys-296 in the glucagon-like peptide-1 (GLP-1) receptor indicates a disulfide bond that is close to the activation pocket. Peptides 31, 2289–2293 (2010)

  18. 18.

    et al. Structure of the full-length glucagon class B G protein-coupled receptor. Nature (this issue)

  19. 19.

    et al. Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 520, 317–321 (2015)

  20. 20.

    et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513, 124–127 (2014)

  21. 21.

    et al. Discovery of a novel glucagon receptor antagonist N-[(4-(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethylphenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes. J. Med. Chem. 55, 6137–6148 (2012)

  22. 22.

    et al. New beta-alanine derivatives are orally available glucagon receptor antagonists. J. Med. Chem. 50, 113–128 (2007)

  23. 23.

    et al. The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem. Lett. 23, 3051–3058 (2013)

  24. 24.

    et al. Insights into the structure of class B GPCRs. Trends Pharmacol. Sci. 35, 12–22 (2014)

  25. 25.

    et al. Positive allosteric modulation of the glucagon-like peptide-1 receptor by diverse electrophiles. J. Biol. Chem. 291, 10700–10715 (2016)

  26. 26.

    et al. A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification. Nat. Chem. Biol. 10, 629–631 (2014)

  27. 27.

    et al. Structural–functional analysis of the third transmembrane domain of the corticotropin-releasing factor type 1 receptor: role in activation and allosteric antagonism. J. Biol. Chem. 289, 18966–18977 (2014)

  28. 28.

    et al. Molecular signatures of G-protein-coupled receptors. Nature 494, 185–194 (2013)

  29. 29.

    , , & Scanning of the glucagon-like peptide-1 receptor localizes G protein-activating determinants primarily to the N terminus of the third intracellular loop. Mol. Endocrinol. 11, 424–432 (1997)

  30. 30.

    et al. Functional elements of the gastric inhibitory polypeptide receptor: Comparison between secretin- and rhodopsin-like G protein-coupled receptors. Biochem. Pharmacol. 96, 237–246 (2015)

  31. 31.

    et al. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20, 967–976 (2012)

  32. 32.

    et al. In vitro expression and analysis of the 826 human G protein-coupled receptors. Protein Cell 7, 325–337 (2016)

  33. 33.

    et al. Rastering strategy for screening and centring of microcrystal samples of human membrane proteins with a sub-10 microm size X-ray synchrotron beam. J. R. Soc. Interface 6 (suppl. 5), S587–S597 (2009)

  34. 34.

    Xds. Acta Crystallogr. D 66, 125–132 (2010)

  35. 35.

    et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007)

  36. 36.

    . et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010)

  37. 37.

    et al. REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallogr. D 60, 2184–2195 (2004)

  38. 38.

    , , & Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010)

  39. 39.

    et al. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr. D 68, 368–380 (2012)

  40. 40.

    et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010)

  41. 41.

    , , , & Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221–234 (2013)

  42. 42.

    et al. Docking covalent inhibitors: a parameter free approach to pose prediction and scoring. J. Chem. Inf. Model. 54, 1932–1940 (2014)

  43. 43.

    et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J. Phys. Chem. B 114, 7830–7843 (2010)

  44. 44.

    , , & Extension of the CHARMM General Force Field to sulfonyl-containing compounds and its utility in biomolecular simulations. J. Comput. Chem. 33, 2451–2468 (2012)

  45. 45.

    et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29, 845–854 (2013)

  46. 46.

    P-LINCS: a parallel linear constraint solver for molecular simulation. J. Chem. Theory Comput. 4, 116–122 (2008)

  47. 47.

    , & Canonical sampling through velocity rescaling. J. Chem. Phys. 126, 014101 (2007)

  48. 48.

    , , , & Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684 (1984)

  49. 49.

    FreeSASA: An open source C library for solvent accessible surface area calculations. F1000 Res. 5, 189 (2016)

Download references


This work was supported by the National Natural Science Foundation of China grants 31330019 (Z.-J.L.), 31500593 (G.S.), 81373463 and 81573479 (D.Y.), the National Health and Family Planning Commission grants 2012ZX09304-011, 2013ZX09401003-005, 2013ZX09507001 and 2013ZX09507-002 (M.-W.W.), Shanghai Science and Technology Development Fund 15DZ2291600 (M.-W.W.), and Ministry of Science and Technology of China grants 2014CB910400 (Z.-J.L.) and 2015CB910104 (Z.-J.L.), the Netherlands eScience Center (NLeSC)/NWO Enabling Technologies project: 3D-e-Chem, grant 027.014.201 (C.d.G.), the European Cooperation in Science and Technology Action CM1207 GLISTEN (C.d.G.), and National Key Research and Development Program of China 2016YCF0905902 (S.Z.). We thank the Cloning, Cell Expression and Protein Purification Core Facilities of iHuman Institute for their support. We thank L. Qu, Y. Feng and C. Ji for their technical assistance, Y. Liu, H. Tao, S. Qin, W. Shui, F. Ni, C. Zhang, J. Cheng, Q. Zhao and V. Cherezov for discussions or contributions at the early stages of this project, and A. Walker and S. Reedtz-Runge for critical review of the manuscript. We thank the Shanghai Municipal Government, ShanghaiTech University and GPCR Consortium for financial support. The synchrotron radiation experiments were performed at the BL41XU of Spring-8 with approval of the Japan Synchrotron Radiation Research Institute (JASRI) (proposal no. 2016B2708 and 2016B2724), and beamline BL17U1 (Shanghai Synchrotron Radiation Facility [SSRF], China). Computational resources were supported by the Shanghai Supercomputer Center, and the Supercomputing Center of ShanghaiTech University.

Author information

Author notes

    • Dehua Yang
    • , Yuxia Wang
    •  & Chris de Graaf

    These authors contributed equally to this work.


  1. iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai 201210, China

    • Gaojie Song
    • , Yuxia Wang
    • , Qingtong Zhou
    • , Kaiwen Liu
    • , Dongsheng Liu
    • , Fan Wu
    • , Yiran Wu
    • , Suwen Zhao
    • , Zhi-Jie Liu
    •  & Raymond C. Stevens
  2. The National Center for Drug Screening and the CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shou Jing Road, Shanghai 201203, China

    • Dehua Yang
    • , Xiaoqing Cai
    • , Antao Dai
    •  & Ming-Wei Wang
  3. Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands

    • Chris de Graaf
  4. School of Pharmacy, Fudan University, 826 Zhang Heng Road, Shanghai 201203, China

    • Shanshan Jiang
    • , Li Ye
    •  & Ming-Wei Wang
  5. School of Life Science and Technology, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai 201210, China

    • Kaiwen Liu
    • , Guangyao Lin
    • , Fan Wu
    • , Suwen Zhao
    • , Beili Wu
    • , Zhi-Jie Liu
    • , Ming-Wei Wang
    •  & Raymond C. Stevens
  6. University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China

    • Kaiwen Liu
    • , Fan Wu
    •  & Beili Wu
  7. Department of Chemistry, Bridge Institute, University of Southern California, 3430 S. Vermont Avenue, Los Angeles, California 90089, USA

    • Gye Won Han
  8. Novo Nordisk, Måløv DK-2760, Denmark

    • Jesper Lau
  9. The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

    • Beili Wu
  10. GPCR Consortium, San Marcos, California 92078, USA

    • Michael A. Hanson
  11. Institute of Molecular and Clinical Medicine, Kunming Medical University, Kunming 650500, China

    • Zhi-Jie Liu


  1. Search for Gaojie Song in:

  2. Search for Dehua Yang in:

  3. Search for Yuxia Wang in:

  4. Search for Chris de Graaf in:

  5. Search for Qingtong Zhou in:

  6. Search for Shanshan Jiang in:

  7. Search for Kaiwen Liu in:

  8. Search for Xiaoqing Cai in:

  9. Search for Antao Dai in:

  10. Search for Guangyao Lin in:

  11. Search for Dongsheng Liu in:

  12. Search for Fan Wu in:

  13. Search for Yiran Wu in:

  14. Search for Suwen Zhao in:

  15. Search for Li Ye in:

  16. Search for Gye Won Han in:

  17. Search for Jesper Lau in:

  18. Search for Beili Wu in:

  19. Search for Michael A. Hanson in:

  20. Search for Zhi-Jie Liu in:

  21. Search for Ming-Wei Wang in:

  22. Search for Raymond C. Stevens in:


G.S., C.d.G. and M.A.H. designed constructs for crystallization. G.S., Y.W., S.J. and K.L. expressed, characterized and screened constructs and ligands for crystallization. G.S., Y.W., S.J. and F.W. purified and crystallized the receptor, optimized crystallization conditions and grew the crystals. G.S., Z.-J.L., M.A.H. and G.W.H. collected diffraction data and solved and refined the structure. G.S., D.Y. and C.d.G. designed and analysed the receptor mutagenesis studies. D.Y., X.C., A.D. and G.L. expressed the receptor, and performed the mutagenesis, functional and ligand-binding assays. Q.Z., Y.W., C.d.G. and S.Z. constructed the GLP-1R–agonist PAM model and performed and analysed MD-simulations on wild-type and mutant GLP-1R. B.W. provided advice on construct design. R.C.S. conceived of the project. R.C.S., M.-W.W., and Z.-J.L. were responsible for the overall project management and edited the manuscript. G.S., C.d.G. and M.A.H. wrote the manuscript with discussions and improvements from D.L., L.Y. and J.L.

Competing interests

J.L. is an employee of Novo Nordisk, a pharmaceutical company focused on GLP-1R for type 2 diabetes. R.C.S. is a founder and board member of Bird Rock Bio, a company focused on GPCR therapeutic antibodies. The remaining authors declare no competing financial interests.

Corresponding authors

Correspondence to Zhi-Jie Liu or Ming-Wei Wang or Raymond C. Stevens.

Reviewer Information Nature thanks G. Lebon, T. W. Schwartz and C. Siebold for their contribution to the peer review of this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.